Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Tracon Pharmaceuticals Inc (TCON)

Tracon Pharmaceuticals Inc (TCON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,210
  • Shares Outstanding, K 2,275
  • Annual Sales, $ 12,050 K
  • Annual Income, $ -3,590 K
  • 60-Month Beta 0.95
  • Price/Sales 0.32
  • Price/Cash Flow 1.06
  • Price/Book N/A
Trade TCON with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.20
  • Number of Estimates 1
  • High Estimate -1.20
  • Low Estimate -1.20
  • Prior Year -7.20
  • Growth Rate Est. (year over year) +83.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.59 +32.70%
on 04/16/24
11.00 -80.82%
on 03/22/24
-5.11 (-70.78%)
since 03/18/24
3-Month
1.59 +32.70%
on 04/16/24
14.75 -85.69%
on 03/13/24
-0.94 (-30.91%)
since 01/18/24
52-Week
1.59 +32.70%
on 04/16/24
36.90 -94.28%
on 04/19/23
-34.29 (-94.20%)
since 04/18/23

Most Recent Stories

More News
Tracon: Q4 Earnings Snapshot

Tracon: Q4 Earnings Snapshot

TCON : 2.11 (-7.86%)
Tracon: Q3 Earnings Snapshot

Tracon: Q3 Earnings Snapshot

TCON : 2.11 (-7.86%)
Tracon: Q2 Earnings Snapshot

Tracon: Q2 Earnings Snapshot

TCON : 2.11 (-7.86%)
Tracon: Q1 Earnings Snapshot

Tracon: Q1 Earnings Snapshot

TCON : 2.11 (-7.86%)
Tracon (TCON) Moves to Buy: Rationale Behind the Upgrade

Tracon (TCON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

TCON : 2.11 (-7.86%)
Tracon: Q4 Earnings Snapshot

Tracon: Q4 Earnings Snapshot

TCON : 2.11 (-7.86%)
Tracon: Q3 Earnings Snapshot

Tracon: Q3 Earnings Snapshot

TCON : 2.11 (-7.86%)
US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved the...

TCON : 2.11 (-7.86%)
TRACON Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a...

TCON : 2.11 (-7.86%)
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

Trial to Continue as Planned...

TCON : 2.11 (-7.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The company's product candidate includes TRC105, TRC205 and TRC102 which are in different clinical stage for cancer, age-related macular degeneration and fibrotic diseases. TRACON Pharmaceuticals, Inc. is headquartered in San Diego, California....

See More

Key Turning Points

3rd Resistance Point 2.56
2nd Resistance Point 2.45
1st Resistance Point 2.28
Last Price 2.11
1st Support Level 2.00
2nd Support Level 1.89
3rd Support Level 1.72

See More

52-Week High 36.90
Fibonacci 61.8% 23.41
Fibonacci 50% 19.25
Fibonacci 38.2% 15.08
Last Price 2.11
52-Week Low 1.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar